

**Microwave-assisted one-pot synthesis of 2-aryl-5,6-dihydro-1,3-thiazines
via reaction between Lawesson's reagent and allyl arylamides derived
from Morita-Baylis-Hillman acetates**

Subhendu Bhowmik, Amita Mishra and Sanjay Batra*

*Medicinal and Process Chemistry Division, Central Drug Research Institute, CSIR, PO
Box 173, Lucknow 226001, India*

e-mail: batra_san@yahoo.co.uk, s_batra@cdri.res.in

Contents

1. Spectroscopic data	S-2
2. copies of ^1H and ^{13}C -NMR spectra	S-7

Methyl 2-[(benzoylamino)(2-bromophenyl)methyl]acrylate (5b). 74 % as a white solid (0.89 g from 1.0 g), mp 100-102 °C; R_f 0.29 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1664 (CONH), 1732 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 3.73 (s, 3H, OCH₃), 6.01 (s, 1H, =CH₂), 6.46 (s, 1H, =CH₂), 6.50 (d, 1H, J = 8.0 Hz, CH), 7.13-7.18 (m, 2H, ArH), 7.26-7.32 (m, 1H, ArH), 7.42-7.46 (m, 3H, ArH), 7.49-7.54 (m, 1H, ArH), 7.58-7.61 (m, 1H, ArH), 7.80-7.83 (m, 2H, ArH and NH); ¹³C NMR (50 MHz, CDCl₃) δ = 52.2, 54.8, 124.3, 127.2, 127.7, 128.3, 128.6, 128.7, 129.5, 131.8, 133.6, 134.0, 138.2, 138.6, 166.2, 166.5; mass (ES+) m/z = 374.0 (M⁺+1), 376.0 (M⁺+1); Anal. Calcd. for C₁₈H₁₆BrNO₃ (Exact mass: 373.0314); C, 57.77; H, 4.31; N, 3.74; Found: C, 57.59; H, 4.37; N, 3.63.

Methyl 2-[(benzoylamino)(2-fluorophenyl)methyl]acrylate (5c). 64 % as a white solid (0.8 g from 1.0 g), mp 62-64 °C; R_f 0.28 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1645 (CONH), 1731 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 3.73 (s, 3H, OCH₃), 6.02 (s, 1H, =CH₂), 6.38 (s, 1H, =CH₂), 6.45 (d, 1H, J = 8.7 Hz, CH), 7.02-7.14 (m, 2H, ArH), 7.41-7.54 (m, 5H, ArH), 7.83 (d, 2H, J = 7.0 Hz, ArH), 8.13 (d, 1H, J = 7.2 Hz, NH); ¹³C NMR (50 MHz, CDCl₃) δ = 50.4, 52.2, 115.9 (J = 21.5Hz), 124.3 (J = 1.8Hz), 127.2, 127.8, 128.5, 128.6, 128.7, 129.6 (J = 8.4 Hz), 130.2, 131.9, 133.7, 134.1, 138.3, 163.2, 166.3, 166.5; mass (ES+) m/z = 314.1 (M⁺+1); Anal. Calcd. for C₁₈H₁₆FNO₃ (Exact mass: 313.1114); C, 69.00; H, 5.15; N, 4.47; Found: C, 68.86; H, 5.33; N, 4.43.

Methyl 2-[(benzoylamino)(4-fluorophenyl)methyl]acrylate (5d). 79 % as a white solid (0.98 g from 1.0 g), 82-84 °C; R_f 0.30 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1658 (CONH), 1731 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 3.74 (s, 3H, OCH₃), 6.03 (s, 1H, =CH₂), 6.20 (d, 1H, J = 8.9 Hz, CH), 6.41 (s, 1H, =CH₂), 7.02 (t, 2H, J = 8.6 Hz, ArH), 7.26-7.34 (m, 2H, ArH), 7.43-7.53 (m, 4H, ArH), 7.84 (d, 2H, J = 7.1 Hz, ArH and NH); ¹³C NMR (50 MHz, CDCl₃) δ = 52.4, 55.1, 115.6, 116.0, 127.3, 128.2, 128.3, 128.4, 128.9, 132.1, 134.3, 135.6, 135.7, 139.0, 160.0, 166.6, 166.8; mass (ES+) m/z = 314.1 (M⁺+1); Anal. Calcd. for C₁₈H₁₆FNO₃ (Exact mass: 313.1114); C, 69.00; H, 5.15; N, 4.47; Found: C, 68.73; H, 5.39; N, 4.36.

Methyl 2-[(benzoylamino)(4-methylphenyl)methyl]acrylate (5e). 63 % as a white solid (0.78 g from 1.0 g) mp 96-98 °C; R_f 0.32 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1656 (CONH), 1733 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 2.32 (s, 3H, CH₃), 3.72 (s, 3H, OCH₃), 6.01 (s, 1H, =CH₂), 6.19 (d, 1H, J = 8.7 Hz, CH), 6.39 (s, 1H, =CH₂), 7.14 (d, 2H, J = 8.0 Hz, ArH), 7.22-7.26 (m, 2H, ArH), 7.38-7.52 (m, 4H, ArH), 7.82-7.84 (m, 2H, ArH and NH); ¹³C NMR (75

MHz, CDCl₃) δ = 21.3, 52.3, 55.4, 126.6, 127.3, 127.8, 128.8, 129.6, 131.9, 134.4, 136.8, 137.5, 139.3, 166.6, 166.8; mass (ES⁺) m/z = 310.1 (M⁺+1). Anal. Calcd. for C₁₉H₁₉NO₃ (Exact mass: 309.1365); C, 73.77; H, 6.19; N, 4.53; Found: C, 73.86; H, 6.23; N, 4.39.

Methyl 2-[(benzoylamino)(2,4-dichlorophenyl)methyl]acrylate (5f). 71 % as a white solid (0.85 g from 1.0 g), mp 116-118 °C; R_f = 0.30 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1639 (CONH), 1729 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 3.74 (s, 3H, OCH₃), 6.02 (s, 1H, =CH₂), 6.44-6.48 (m, 2H, CH and =CH₂), 7.24-7.26 (m, 1H, ArH), 7.41-7.50 (m, 6H, ArH), 7.81 (d, 2H, J = 6.4 Hz, ArH and NH); ¹³C NMR (75 MHz, CDCl₃) δ = 52.4, 127.2, 127.4, 128.8, 129.0, 129.4, 130.0, 132.0, 133.8, 134.4, 134.5, 135.7, 137.4, 166.2, 166.5; mass (ES⁺) m/z = 364.0 (M⁺+1), 366.0 (M⁺+3). Anal. Calcd. for C₁₈H₁₅Cl₂NO₃ (Exact mass: 363.0429); C, 59.36; H, 4.15; N, 3.85; Found: C, 59.42; H, 4.33; N, 3.73.

Methyl 2-[(benzoylamino)(2-chloro-4-nitrophenyl)methyl]acrylate (5g). 88 % as a white solid (1.05 g from 1.0 g), mp 160-162 °C; R_f = 0.31 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1637 (CONH), 1734 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 3.77 (s, 3H, OCH₃), 6.10 (s, 1H, =CH₂), 6.50 (s, 1H, =CH₂), 6.56 (d, 1H, J = 8.2 Hz, CH), 7.47 (t, 2H, J = 6.6 Hz, ArH), 7.53-7.58 (m, 3H, ArH), 7.82-7.85 (m, 2H, ArH), 8.08-8.12 (m, 1H, ArH), 8.39 (d, 1H, J = 2.9 Hz, NH); ¹³C NMR (50 MHz, CDCl₃) δ = 52.6, 123.6, 123.9, 127.3, 128.9, 130.1, 131.1, 132.2, 133.5, 136.8, 139.4, 140.6, 146.8, 166.2, 166.5; mass (ES⁺) m/z = 375.1 (M⁺+1), 377.1 (M⁺+3); Anal. Calcd. for C₁₈H₁₅ClN₂O₅ (Exact mass: 374.0670); C, 57.69; H, 4.03; N, 7.47; Found: C, 57.59; H, 4.23; N, 7.56.

Methyl 2-[(benzoylamino)(2-thienyl)methyl]acrylate (5h). 72 % as a yellow solid (0.90 g from 1.0 g), mp 67-69 °C; R_f = 0.29 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1655 (CONH), 1728 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 3.78 (s, 3H, OCH₃), 6.06 (s, 1H, =CH₂), 6.42 (d, 2H, J = 9.9 Hz, CH and =CH₂), 6.96 (t, 2H, J = 3.5 Hz, ArH), 7.23 (t, 1H, J = 1.4 Hz, ArH), 7.43-7.60 (m, 3H, ArH), 7.61 (d, 1H, J = 8.1 Hz, ArH), 7.82-7.85 (m, 2H, ArH and NH); ¹³C NMR (50 MHz, CDCl₃) δ = 52.1, 52.3, 124.8, 125.1, 127.3, 128.2, 128.8, 131.9, 134.1, 138.7, 144.1, 166.3, 166.5; mass (ES⁺) m/z = 302.1 (M⁺+1). Anal. Calcd. for C₁₆H₁₅NO₃S (Exact mass: 301.0773); C, 63.77; H, 5.02; N, 4.65; Found: C, 63.46; H, 5.11; N, 4.63.

N-(2-Cyano-1-phenylallyl)benzamide (6a). 75 % as a white solid (0.98 g from 1.0 g), mp 97-99 °C; R_f = 0.27 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1638 (CONH), 2221 (CN) cm⁻¹; ¹H NMR

(300 MHz, CDCl₃) δ = 5.95 (d, 1H, J = 7.7 Hz, CH), 6.09 (d, 1H, J = 0.9 Hz, =CH₂), 6.15 (s, 1H, =CH₂), 6.59 (d, 1H, J = 5.7 Hz, NH), 7.42-7.52 (m, 6H, ArH), 7.56 (d, 1H, J = 7.5 Hz, ArH), 7.81 (d, 2H, J = 7.1 Hz, ArH); ¹³C NMR (75 MHz, CDCl₃) δ = 55.1, 117.3, 123.7, 127.5, 127.6, 127.8, 128.0, 128.4, 128.8, 129.2, 131.3, 131.4, 132.3, 133.6, 137.1, 166.6; mass (ES+) m/z = 263.1 (M⁺+1). Anal. Calcd. for C₁₇H₁₄N₂O (Exact mass: 262.1106); C, 77.84; H, 5.38; N, 10.68; Found: C, 77.97; H, 5.56; N, 10.43.

***N*-(1-(2-Bromophenyl)-2-cyanoallyl)benzamide (6b)**. 83 % as a white solid (1.01 g from 1.0 g), mp 108-110 °C; R_f = 0.24 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1649 (CONH), 2223 (CN) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 6.04 (d, 1H, J = 1.4 Hz, =CH₂), 6.19 (d, 1H, J = 1.2 Hz, =CH₂), 6.28 (d, 1H, J = 7.7 Hz, CH), 6.72 (d, 1H, J = 6.9 Hz, NH), 7.25-7.30 (m, 1H, ArH), 7.38-7.57 (m, 5H, ArH), 7.66 (d, 1H, J = 7.2 Hz, ArH), 7.81 (d, 2H, J = 7.1 Hz, ArH); ¹³C NMR (50 MHz, CDCl₃) δ = 55.7, 117.1, 122.5, 124.0, 127.3, 128.4, 128.9, 129.2, 130.6, 132.3, 132.5, 133.3, 134.1, 136.2, 166.9; mass (ES+) m/z = 341.1 (M⁺+1), 343.1 (M⁺+3); Anal. Calcd. for C₁₇H₁₃BrN₂O (Exact mass: 340.0211); C, 59.84; H, 3.84; N, 8.21; Found: C, 59.69; H, 3.88; N, 8.37.

***N*-(2-Cyano-1-(2-fluorophenyl)allyl)benzamide (6c)**. 70 % as a white solid (0.90 g from 1.0 g), mp 132-134 °C; R_f = 0.30 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1650 (CONH), 2230 (CN) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 6.00 (d, 1H, J = 2.0 Hz, =CH₂), 6.11 (d, 1H, J = 2.1 Hz, =CH₂), 6.18 (d, 1H, J = 12.5 Hz, CH), 6.83 (d, 1H, J = 10.4 Hz, NH), 7.11-7.22 (m, 2H, ArH), 7.37-7.55 (m, 5H, ArH), 7.79-7.86 (m, 2H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ = 51.6 (J = 2.0 Hz), 116.8 (J = 11.4 Hz), 123.1, 124.3 (J = 13.0 Hz), 125.4 (J = 3.5 Hz), 127.3, 128.8, 129.0, 129.3 (J = 3.6 Hz), 130.9, 131.3 (J = 23.9 Hz), 132.2 (J = 9.7 Hz), 133.4, 160.7 (J = 246.0 Hz), 166.9; mass (ES+) m/z = 281.1 (M⁺+1); Anal. Calcd. for C₁₇H₁₃FN₂O (Exact mass: 280.1012); C, 72.85; H, 4.67; N, 9.99; Found: C, 72.66; H, 4.39; N, 9.65.

***N*-(2-Cyano-1-(4-fluorophenyl)allyl)benzamide (6d)**. 75 % as a white solid (0.96 g from 1.0 g), mp 110-112 °C; R_f = 0.29 (hexanes: EtOAc, 70:30, v/v); ν_{\max} (KBr) 1648 (CONH), 2227 (CN) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 5.95 (d, 1H, J = 7.7 Hz, CH), 6.09 (d, 1H, J = 1.2 Hz, =CH₂), 6.16 (s, 1H, =CH₂), 6.55 (d, 1H, J = 6.5 Hz, NH), 7.09-7.15 (m, 2H, ArH), 7.37-7.55 (m, 5H, ArH), 7.79 (t, 2H, J = 7.0 Hz, ArH); ¹³C NMR (75 MHz, CDCl₃ + DMSO-*d*₆) δ = 54.4, 114.5, 115.7, 117.9, 123.7, 127.8, 128.5 (J = 18.8 Hz), 129.4, 130.1, 130.1 (J = 8.3 Hz), 130.8, 131.8, 132.9 (J = 11.2 Hz), 133.8, 134.1 (J = 2.9 Hz), 162.0 (J = 243.0 Hz), 166.4; mass (ES+) m/z = 281.1

($M^+ + 1$); Anal. Calcd. for $C_{17}H_{13}FN_2O$ (Exact mass: 280.1012); C, 72.85; H, 4.67; N, 9.99; Found: C, 72.59; H, 4.46; N, 9.76.

***N*-(2-Cyano-1-(4-methylphenyl)allyl)benzamide (6e)**. 66 % as a white solid (0.85 g from 1.0 g), mp 87-89 °C; $R_f = 0.28$ (hexanes: EtOAc, 70:30, v/v); ν_{max} (KBr) 1647 (CONH), 2225 (CN) cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) $\delta = 2.37$ (s, 3H, CH_3), 5.89 (d, 1H, $J = 7.4$ Hz, CH), 6.08 (d, 1H, $J = 1.0$ Hz, = CH_2), 6.13 (s, 1H, = CH_2), 6.54-6.61 (d, 1H, $J = 6.6$ Hz, NH), 7.22-7.31 (m, 4H, ArH), 7.45 (t, 2H, $J = 7.0$ Hz, ArH), 7.53 (d, 1H, $J = 7.1$ Hz, ArH), 7.78 (d, 2H, $J = 3.9$ Hz, ArH); ^{13}C NMR (50 MHz, $CDCl_3$) $\delta = 21.2, 56.1, 117.3, 123.8, 126.4, 127.1, 127.3, 127.9, 128.5, 128.8, 130.1, 131.6, 132.2, 133.6, 134.1, 139.0, 167.0$; mass (ES+) $m/z = 277.1$ ($M^+ + 1$). Anal. Calcd. for $C_{17}H_{13}BrN_2O$ (Exact mass: 276.1263); C, 78.24; H, 5.84; N, 10.14; Found: C, 78.06; H, 5.97; N, 10.07.

Methyl 2-[(2-furoylamino)(phenyl)methyl]acrylate (8A). 68 % as a white solid (0.83 g from 1.0 g), mp 65-67 °C; $R_f = 0.26$ (hexanes: EtOAc, 70:30, v/v); ν_{max} (KBr) 1646 (CONH), 1725 (CO_2Me) cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) $\delta = 3.72$ (s, 3H, OCH_3), 6.00 (s, 1H, = CH_2), 6.19 (d, 1H, $J = 9.0$ Hz, CH), 6.41 (s, 1H, = CH_2), 6.50-6.52 (m, 1H, NH), 7.16 (d, 1H, $J = 3.2$ Hz, ArH), 7.26-7.35 (m, 5H, ArH), 7.46 (d, 2H, $J = 0.9$ Hz, ArH); ^{13}C NMR (75 MHz, $CDCl_3$) $\delta = 52.2, 54.4, 112.3, 114.9, 126.6, 127.7, 127.8, 128.5, 128.8, 139.1, 139.4, 144.3, 147.8, 157.5, 166.3$; mass (ES+) $m/z = 286.1$ ($M^+ + 1$). Anal. Calcd. for $C_{16}H_{15}NO_4$ (Exact mass: 285.1001); C, 67.36; H, 5.30; N, 4.91; Found: C, 67.09; H, 5.02; N, 4.77.

Methyl 2-[phenyl(1-phenyl-5-(4-methylphenyl)-1H-pyrazole-3-carboxamido)methyl]acrylate (8B). 65 % as a yellow solid (1.25 g from 1.0 g), mp 71-73 °C; $R_f = 0.27$ (hexanes: EtOAc, 70:30, v/v); ν_{max} (KBr) 1662 (CONH), 1732 (CO_2Me) cm^{-1} ; 1H NMR (200 MHz, $CDCl_3$) $\delta = 2.34$ (s, 3H, CH_3), 3.69 (s, 3H, OCH_3), 5.99 (s, 1H, = CH_2), 6.26 (d, 1H, $J = 5.9$ Hz, CH), 6.43 (s, 1H, = CH_2), 7.03-7.10 (m, 5H, ArH), 7.26-7.36 (m, 9H, ArH), 7.77 (d, 1H, $J = 5.6$ Hz, NH); ^{13}C NMR (50 MHz, $CDCl_3$) $\delta = 21.4, 52.1, 54.2, 108.2, 125.6, 126.9, 127.0, 127.7, 128.2, 128.7, 128.8, 129.1, 129.4, 129.8, 138.8, 139.6, 139.8, 145.2, 146.8, 161.2, 166.3$; mass (ES+) $m/z = 452.2$ ($M^+ + 1$). Anal. Calcd. for $C_{28}H_{25}N_3O_3$ (Exact mass: 451.1896); C, 74.48; H, 5.58; N, 9.31; Found: C, 74.66; H, 5.79; N, 9.40.

Methyl 2-[(3-(2-chlorophenyl)isoxazole-5-carboxamido)(phenyl)methyl]acrylate (8C). 77 % as a white solid (1.30 g from 1.0 g), mp 130-132 °C; $R_f = 0.27$ (hexanes: EtOAc, 70:30, v/v); ν_{max} (KBr) 1637 (CONH), 1733 (CO_2Me) cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) $\delta = 3.74$ (s, 3H, OCH_3),

6.02 (s, 1H, =CH₂), 6.21 (d, 1H, *J* = 8.9 Hz, CH), 6.46 (s, 1H, =CH₂), 7.30-7.46 (m, 8H, ArH), 7.51-7.54 (m, 1H, ArH), 7.71-7.77 (m, 2H, ArH and NH); ¹³C NMR (75 MHz, CDCl₃) δ = 52.3, 55.0, 108.8, 126.6, 127.3, 127.5, 128.1, 129.0, 130.7, 131.1, 131.5, 133.2, 138.7, 155.1, 162.2, 163.0, 166.1; mass (ES+) *m/z* = 397.1 (M⁺+1), 399.1 (M⁺+3); Anal. Calcd. for C₂₁H₁₇ClN₂O₄ (Exact mass: 396.0877); C, 63.56; H, 4.32; N, 7.06; Found: C, 63.43; H, 4.23; N, 6.92.

Methyl 2-[[cyclohexylcarbonyl]amino](phenyl)methyl]acrylate (8D). 65 % as a white solid (0.83 g from 1.0 g), mp 91-93 °C; *R*_f = 0.24 (hexanes: EtOAc, 70:30, v/v), mp 91-93 °C; *v*_{max} (KBr) 1672 (CONH), 1719 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 1.27-1.31 (m, 2H, CH₂), 1.41-1.53 (m, 2H, CH₂), 1.68-1.90 (m, 2H, CH₂), 2.12-2.22 (m, 1H, CH), 3.69 (s, 3H, OCH₃), 5.92 (s, 1H, =CH₂), 6.01 (d, 1H, *J* = 5.7 Hz, CH), 6.36 (s, 1H, =CH₂), 7.24-7.34 (m, 6H, ArH and NH); ¹³C NMR (50 MHz, CDCl₃ + DMSO-*d*₆) δ = 25.3, 29.1, 29.3, 44.9, 51.5, 53.7, 72.5, 126.4, 126.5, 127.2, 128.2, 139.1, 139.6, 166.4, 176.3; mass (ES+) *m/z* = 302.1 (M⁺+1). Anal. Calcd. for C₁₈H₂₃NO₃ (Exact mass: 301.1678); C, 71.73; H, 7.69; N, 4.65; Found: C, 71.49; H, 7.72; N, 4.56;

Methyl 2-[[cyclopropylcarbonyl]amino](phenyl)methyl]acrylate (8E). 73 % as a white solid (0.80 g from 1.0 g), mp 82-84 °C; *R*_f = 0.29 (hexanes: EtOAc, 70:30, v/v), mp 82-84 °C; *v*_{max} (KBr) 1642 (CONH), 1731 (CO₂Me) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 0.73-0.82 (m, 2H, CH₂), 0.98-1.03 (m, 2H, CH₂), 1.38-1.48 (m, 1H, CH), 3.70 (s, 3H, OCH₃), 5.96 (s, 1H, =CH₂), 6.04 (d, 1H, *J* = 13.3 Hz, CH), 6.38 (s, 1H, =CH₂), 6.75 (d, 1H, *J* = 12.5 Hz, NH), 7.23-7.42 (m, 5H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ = 7.4, 7.5, 15.0, 52.1, 55.0, 126.6, 127.5, 127.6, 128.7, 128.9, 129.8, 139.4, 139.9, 166.5, 172.8; mass (ES+) *m/z* = 260.1 (M⁺+1). Anal. Calcd. for C₁₅H₁₇NO₃ (Exact mass: 259.1208); C, 69.48; H, 6.61; N, 5.40; Found: C, 69.29; H, 6.76; N, 5.13.

(4*R*,5*S*)-4-(4-Fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carbonitrile. 3 % as brown oil (22 mg from 500 mg); *R*_f = 0.27 (hexanes: EtOAc, 80:20, v/v); *v*_{max} (Neat) 2214 (CN) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ = 3.32 (dd, 1H, *J*₁ = 12.3 Hz, *J*₂ = 6.1 Hz, CH₂), 3.39-3.44 (m, 1H, CH), 3.55 (dd, 1H, *J*₁ = 12.3 Hz, *J*₂ = 3.6 Hz, CH₂), 5.09 (d, 1H, *J* = 3.4 Hz, CH), 7.13 (t, 2H, *J* = 8.6 Hz, ArH), 7.38-7.51 (m, 5H, ArH), 7.86-7.91 (m, 2H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ = 27.2, 29.8, 59.9, 115.7, 116.0, 126.7, 127.0, 127.6, 128.6, 128.7, 129.3, 129.4, 131.4, 132.1, 135.0, 159.7, 163.8; mass (ES+) *m/z* = 297.0 (M⁺+1); DART-HRMS calcd. for C₁₇H₁₄FN₂S 297.0862, Found 297.0863.




Fig:S-1 ¹H spectrum of Methyl 2-[(benzoylamino)(phenyl)methyl]acrylate (5a).




Fig:S-2 ¹³C spectrum of Methyl (E)-2-({5-[1-(benzylamino)-1-methylpropyl]-1H-1,2,3,4-tetraazol-1-yl)methyl}-3-(4-fluorophenyl)prop-2-enoate (5a).




Fig:S- ¹H spectrum of Methyl 2-[(benzoylamino)(2-bromophenyl)methyl]acrylate (5b).




Fig:S-4 ¹³C spectrum of Methyl 2-[(benzoylamino)(2-bromophenyl)methyl]acrylate (5b).




Fig:S-5 ¹H spectrum of Methyl 2-[(benzoylamino)(2-fluorophenyl)methyl]acrylate (5c).




Fig:S-6 ¹³C spectrum of Methyl 2-[(benzoylamino)(2-fluorophenyl)methyl]acrylate (5c).




Fig:S-7 ¹H spectrum of Methyl 2-[(benzoylamino)(4-fluorophenyl)methyl]acrylate (5d).




Fig:S-8 ¹³C spectrum of Methyl 2-[(benzoylamino)(4-fluorophenyl)methyl]acrylate (5d).




Fig:S-9 ¹H spectrum of Methyl 2-[(benzoylamino)(4-methylphenyl)methyl]acrylate (5e).




Fig:S-10 ¹³C spectrum of Methyl 2-[(benzoylamino)(4-methylphenyl)methyl]acrylate (5e).




Fig:S-11 ¹H spectrum of Methyl 2-[(benzoylamino)(2,4-dichlorophenyl)methyl]acrylate (5f).




Fig:S-12 ¹³C spectrum of Methyl 2-[(benzoylamino)(2,4-dichlorophenyl)methyl]acrylate (5f).




Fig:S-13 ^1H spectrum of Methyl 2-[(benzoylamino)(2-chloro-4-nitrophenyl)methyl]acrylate (5g).




Fig:S-14 ^{13}C spectrum of Methyl 2-[(benzoylamino)(2-chloro-4-nitrophenyl)methyl]acrylate (5g).




Fig:S-15 ¹H spectrum of Methyl 2-[(benzoylamino)(2-thienyl)methyl]acrylate (5h).




Fig:S-16 ¹³C spectrum of Methyl 2-[(benzoylamino)(2-thienyl)methyl]acrylate (5h).




Fig:S-17 ¹H spectrum of *N*-(2-cyano-1-phenylallyl)benzamide (6a).




Fig:S-18 ¹³C spectrum of *N*-(2-cyano-1-phenylallyl)benzamide (6a).




Fig:S-19 ¹H spectrum of *N*-(1-(2-bromophenyl)-2-cyanoallyl)benzamide (6b).




Fig:S-20 ¹³C spectrum of *N*-(1-(2-bromophenyl)-2-cyanoallyl)benzamide (6b).




Fig:S-21 ^1H spectrum of *N*-[2-cyano-1-(2-fluorophenyl)allyl]benzamide (6c).




Fig:S-22 ^{13}C spectrum of *N*-[2-cyano-1-(2-fluorophenyl)allyl]benzamide (6c).




Fig:S-23 ^1H spectrum of *N*-[2-cyano-1-(4-fluorophenyl)allyl]benzamide (6d).




Fig:S-24 ^{13}C spectrum of *N*-[2-cyano-1-(4-fluorophenyl)allyl]benzamide (6d).




Fig:S-25 ^1H spectrum of *N*-(2-cyano-1-*p*-tolylallyl)benzamide (6e).




Fig:S-26 ^{13}C spectrum of *N*-(2-cyano-1-*p*-tolylallyl)benzamide (6e).




Fig:S-27 ^1H spectrum of Methyl (4*R*,5*S*)-2,4-diphenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn7a*).




Fig:S-28 ^{13}C spectrum of Methyl (4*R*,5*S*)-2,4-diphenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn7a*).




Fig:S-29 ^1H spectrum of Methyl (4R,5R)-2,4-diphenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7a).




Fig:S-30 ^{13}C spectrum of Methyl (4R,5R)-2,4-diphenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7a).




Fig:S-31 ¹H spectrum of Methyl (4R,5S)-4-(2-bromophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (syn7b).




Fig:S-32 ¹³C spectrum of Methyl (4R,5S)-4-(2-bromophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (syn7b).




Fig:S-33 ¹³C spectrum of Methyl (4R,5S)-4-(2-bromophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7b).




Fig:S-34 ¹³C spectrum of Methyl (4R,5S)-4-(2-bromophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7b).




Fig:S-35 ^1H spectrum of Methyl (4*R*,5*S*)-4-(2-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn* 7*c*).




Fig:S-36 ^{13}C spectrum of Methyl (4*R*,5*S*)-4-(2-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn* 7*c*).




Fig:S-37 ¹H spectrum of Methyl (4R,5R)-4-(2-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7c).




Fig:S-38 ¹³C spectrum of Methyl (4R,5R)-4-(2-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7c).




Fig:S-39 ^1H spectrum of Methyl (4*R*,5*S*)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn7d*).




Fig:S-40 ^{13}C spectrum of Methyl (4*R*,5*S*)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn7d*).




Fig:S-41 DEPT-90 spectrum of Methyl (4R,5S)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*syn7d*).




Fig:S-42 DEPT-135 spectrum of Methyl (4R,5S)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*syn7d*).




Fig:S-43 NOESY spectrum of Methyl (4R,5S)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*syn* 7d).




Fig:S-44 ¹H spectrum of Methyl (4R,5R)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7d).




Fig:S-45 ^{13}C spectrum of Methyl (4*R*,5*R*)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*anti* 7d).




Fig:S-46 DEPT-90 spectrum of Methyl (4*R*,5*R*)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*anti* 7d).




Fig:S-47 DEPT-135 spectrum of Methyl (4R,5R)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7d).




Fig:S-48 NOESY spectrum of Methyl (4R,5R)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7d).




Fig:S-49 ^1H spectrum of Methyl (4*R*,5*S*)-4-(4-methylphenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate(*syn* 7e).




Fig:S-50 ^{13}C spectrum of Methyl (4*R*,5*S*)-4-(4-methylphenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn*7e).




Fig:S-51 ¹H spectrum of Methyl (4R,5R)-4-(4-methylphenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7e).




Fig:S-52 ¹³C spectrum of Methyl (4R,5R)-4-(4-methylphenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7e).




Fig:S-53 ^1H spectrum of Methyl 4-(2,4-dichlorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (7f).




Fig:S-54 ^{13}C spectrum of Methyl 4-(2,4-dichlorophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (7f).




Fig:S-55 ^1H spectrum of Methyl 4-(2-chloro-4-nitrophenyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (7g).




Fig:S-56 ^{13}C spectrum of Methyl 4-(2-chloro-4-nitrophenyl)-2-phenyl-5,6-dihydro-4H-1,3-oxazine-5-carboxylate (7g).




Fig:S-57 ^1H spectrum of Methyl (4*R*,5*S*)-4-(2-thienyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn* 7*h*).




Fig:S-58 ^{13}C spectrum of Methyl (4*R*,5*S*)-4-(2-thienyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn* 7*h*).




Fig:S-59 ¹H spectrum of Methyl (4R,5R)-4-(2-thienyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7h).




Fig:S-60 ¹³C spectrum of Methyl (4R,5R)-4-(2-thienyl)-2-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 7h).




Fig:S-61 ^1H spectrum of (4*R*,5*R*)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carbonitrile.




Fig:S-62 ^{13}C spectrum of (4*R*,5*R*)-4-(4-fluorophenyl)-2-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carbonitrile.




Fig:S-63 ¹H spectrum of Methyl 2-[(2-furoylamino)(phenyl)methyl]acrylate (8A).




Fig:S-64 ¹³C spectrum of Methyl 2-[(2-furoylamino)(phenyl)methyl]acrylate (8A).




Fig:S-65 ¹H spectrum of Methyl 2-(phenyl(1-phenyl-5-p-tolyl-1H-pyrazole-3-carboxamido)methyl)acrylate (8B).




Fig:S-66 ¹³C spectrum of Methyl 2-[phenyl(1-phenyl-5-p-tolyl-1H-pyrazole-3-carboxamido)methyl]acrylate (8B).




Fig:S-67 ¹H spectrum of Methyl 2-[(3-(2-chlorophenyl)isoxazole-5-carboxamido)(phenyl)methyl]acrylate (8C).




Fig:S-68 ¹³C spectrum of Methyl 2-[(3-(2-chlorophenyl)isoxazole-5-carboxamido)(phenyl)methyl]acrylate (8C).




Fig:S-69 ^1H spectrum of Methyl 2-[[[(cyclohexylcarbonyl)amino](phenyl)methyl]acrylate (8D).




Fig:S-70 ^{13}C spectrum of Methyl 2-[[[(cyclohexylcarbonyl)amino](phenyl)methyl]acrylate (8D).




Fig:S-71 ¹H spectrum of Methyl 2-[[[(cyclopropylcarbonyl)amino](phenyl)methyl]acrylate (8E).




Fig:S-72 ¹³C spectrum of Methyl 2-[[[(cyclopropylcarbonyl)amino](phenyl)methyl]acrylate (8E).




Fig:S-73 ^1H spectrum of Methyl (4*R*,5*S*)-2-(2-furyl)-4-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn* 9A).




Fig:S-74 ^{13}C spectrum of Methyl (4*R*,5*S*)-2-(2-furyl)-4-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*syn* 9A).




Fig:S-75 ¹H spectrum of Methyl (4R,5R)-2-(2-furyl)-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 9A).




Fig:S-76 ¹³C spectrum of Methyl (4R,5R)-2-(2-furyl)-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 9A).




Fig:S-77 ^1H spectrum of Methyl (4R,5S)-2-[5-(4-methylphenyl)-1-phenyl-1H-pyrazol-3-yl]-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*syn* 9B).




Fig:S-78 ^{13}C spectrum of Methyl (4R,5S)-2-[5-(4-methylphenyl)-1-phenyl-1H-pyrazol-3-yl]-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*syn* 9B).




Fig:S-79 ^1H spectrum of Methyl (4R,5R)-2-[5-(4-methylphenyl)-1-phenyl-1H-pyrazol-3-yl]-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 9B).




Fig:S-80 ^{13}C spectrum of Methyl (4R,5R)-2-[5-(4-methylphenyl)-1-phenyl-1H-pyrazol-3-yl]-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (*anti* 9B).




Fig:S-81 ^1H spectrum of Methyl (4*R*,5*S*)-2-2-[5-(2-chlorophenyl)isoxazol-3-yl]-4-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*anti* 9*C*).




Fig:S-82 ^{13}C spectrum of Methyl (4*R*,5*S*)-2-2-[5-(2-chlorophenyl)isoxazol-3-yl]-4-phenyl-5,6-dihydro-4*H*-1,3-thiazine-5-carboxylate (*anti* 9*C*).




Fig:S-83 ^1H spectrum of Methyl 2-cyclohexyl-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (9D).




Fig:S-84 ^{13}C spectrum of Methyl 2-cyclohexyl-4-phenyl-5,6-dihydro-4H-1,3-thiazine-5-carboxylate (9D).




Fig:S-85 ¹H spectrum of Methyl (Z)-2-[[[3-carbothionyl-5-(4-methylphenyl)-1-phenyl-1H-pyrazole)amino]methyl]-3-phenylprop-2-enoate (10B).




Fig:S-86 ¹³C spectrum of Methyl (Z)-2-[[[3-carbothionyl-5-(4-methylphenyl)-1-phenyl-1H-pyrazole)amino]methyl]-3-phenylprop-2-enoate (10B).




Fig:S-87 ^1H spectrum of Methyl (Z)-2-[[cyclopropylcarbothioyl]amino]methyl-3-phenylprop-2-enoate (10E).




Fig:S-88 ^{13}C spectrum of Methyl (Z)-2-[[cyclopropylcarbothioyl]amino]methyl-3-phenylprop-2-enoate (10E).